9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma

MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma

Estimated reading time: < 1 min

Condition: Mesothelioma

Estimated Enrollment: 20

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Intratumoral ratio of CD8 T cells to regulatory T cells (CD8/Treg). [Ratio],  The percentage of inducible T-cell co-stimulator (ICOS) + CD4 T cells.,  The tumor expression programmed death-ligand 1 (PD-L1). [Semi-quantitative assessment: 0, 1+, 2+, 3+, 4+],

Interventions: MEDI4736, Tremelimumab

Phase:

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label),Primary Purpose: Other

Primary Completion Date: December 1, 2019

Completion Date: December 1, 2019

Last  Posted Date: January 16, 2019

Location: Baylor St Lukes, Houston, Texas, United States

Website Link: https://ClinicalTrials.gov/show/NCT02592551

Was this article helpful?
Dislike 0